IRIS
TASSONE, PIERFRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.651
AS - Asia 6.080
EU - Europa 2.936
SA - Sud America 1.463
AF - Africa 135
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 20
Totale 19.310
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.295
SG - Singapore 2.790
CN - Cina 1.365
IT - Italia 1.349
BR - Brasile 1.086
VN - Vietnam 643
IN - India 621
SE - Svezia 406
GB - Regno Unito 373
DE - Germania 281
CA - Canada 251
AR - Argentina 135
HK - Hong Kong 134
FI - Finlandia 110
BD - Bangladesh 80
ID - Indonesia 79
EC - Ecuador 71
MX - Messico 68
NL - Olanda 61
IQ - Iraq 52
RU - Federazione Russa 52
FR - Francia 51
CO - Colombia 41
PK - Pakistan 40
ES - Italia 38
RO - Romania 38
UA - Ucraina 36
ZA - Sudafrica 35
JO - Giordania 33
JP - Giappone 32
PY - Paraguay 32
CL - Cile 30
VE - Venezuela 30
TR - Turchia 28
PL - Polonia 26
EG - Egitto 24
SA - Arabia Saudita 23
EU - Europa 22
IR - Iran 22
PE - Perù 21
CZ - Repubblica Ceca 19
LT - Lituania 16
AE - Emirati Arabi Uniti 15
AT - Austria 15
MA - Marocco 15
AU - Australia 13
UY - Uruguay 13
UZ - Uzbekistan 13
IE - Irlanda 12
KE - Kenya 12
KR - Corea 12
MY - Malesia 11
TN - Tunisia 11
KZ - Kazakistan 10
PT - Portogallo 10
PH - Filippine 9
EE - Estonia 8
ET - Etiopia 8
IL - Israele 8
LB - Libano 8
NG - Nigeria 8
AZ - Azerbaigian 7
DZ - Algeria 7
SN - Senegal 7
BG - Bulgaria 6
GT - Guatemala 6
NP - Nepal 6
CH - Svizzera 5
CY - Cipro 5
DO - Repubblica Dominicana 5
HN - Honduras 5
PS - Palestinian Territory 5
TT - Trinidad e Tobago 5
JM - Giamaica 4
NZ - Nuova Zelanda 4
TW - Taiwan 4
AL - Albania 3
BN - Brunei Darussalam 3
CR - Costa Rica 3
GE - Georgia 3
HR - Croazia 3
HU - Ungheria 3
KG - Kirghizistan 3
KW - Kuwait 3
LK - Sri Lanka 3
LV - Lettonia 3
NI - Nicaragua 3
OM - Oman 3
PA - Panama 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
GR - Grecia 2
GY - Guiana 2
KI - Kiribati 2
MD - Moldavia 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
AO - Angola 1
Totale 19.292
Salva come PNG Salva come JPEG
Città #
San Jose 1.550
Chandler 906
Singapore 876
Ashburn 802
Dallas 509
Santa Clara 477
Hefei 429
Bengaluru 428
Milan 398
Lawrence 383
Princeton 383
Chicago 271
London 253
Ho Chi Minh City 252
Beijing 225
Wilmington 224
Munich 211
Ottawa 165
Catanzaro 156
Hanoi 125
Hong Kong 122
Des Moines 111
São Paulo 89
Boardman 85
Turku 73
Los Angeles 72
New York 62
Rome 55
Shanghai 49
Rio de Janeiro 44
Guangzhou 42
Pune 40
Naples 39
Helsinki 36
The Dalles 34
Norwalk 32
Brooklyn 31
Council Bluffs 31
San Francisco 31
Haiphong 30
Redwood City 30
Redmond 28
Montreal 27
Da Nang 26
Amman 25
Chennai 25
Biên Hòa 24
Quito 23
Warsaw 23
Manchester 21
Orem 21
Parma 21
Atlanta 20
Baghdad 20
Columbus 19
Curitiba 19
Tokyo 19
Boston 18
Phoenix 18
Stockholm 18
Thái Bình 18
Guayaquil 17
Mexico City 17
Salvador 17
Charlotte 16
San Nicola Manfredi 16
Delhi 15
Denver 15
Dhaka 15
Porto Alegre 15
Amsterdam 14
Olomouc 14
Reggio Calabria 14
West Jordan 14
Brasília 13
Campinas 13
Horia 13
Johannesburg 13
Madrid 13
Mountain View 13
Tashkent 13
Washington 13
Aversa 12
Belo Horizonte 12
Buenos Aires 12
Carbonia 12
Frankfurt am Main 12
Montevideo 12
Nairobi 12
Palermo 12
Recife 12
Seattle 12
Thái Nguyên 12
Timisoara 12
Vallefiorita 12
Augusta 11
Cosenza 11
Hanover 11
Lima 11
Santiago 11
Totale 11.108
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 453
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 138
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 110
miR-22 suppresses DNA ligase III addiction in multiple myeloma 102
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 98
An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 96
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 93
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 87
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 86
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 85
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 84
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 82
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer 82
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 81
277 POSTER An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 80
A 5 ' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells 80
Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43 79
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 79
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 78
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 78
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 78
Pyrrolo[2′,3′:3,4]cyclohepta[1,2- d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types 77
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 76
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 75
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 74
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 74
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 74
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 74
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 74
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 73
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report 73
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 73
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 73
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 73
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 72
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 72
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 71
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 71
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 70
Fetal ontogeny and tumor expression of the early thymic antigen UN1 70
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 70
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 69
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 68
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 68
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 67
Associazione di antagonisti di IL-6 e farmaci anti-proliferativi (depositato il 10.3.2005 n. RM2005A000103) 67
Differential microRNAs expression profile in coronary thrombi from patients with no-reflow after primary PCI 67
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 67
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 67
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 66
Mir-34: a new weapon against cancer? 65
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 65
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 65
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells (CO-FIRST AUTHOR) 65
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 64
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 64
A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells 64
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 64
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 64
Biochemical modification of an Interleukin-6 antagonist to target myeloma cells in the bone marrow microenvironment 62
Transcriptional regulation of the mismatch repair gene hMLH1 62
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 61
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 61
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 61
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 61
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 61
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 61
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 61
miR-221/222 inhibitors for the treatment of multiple myeloma 60
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 59
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia 59
HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells 59
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 59
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 59
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 59
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth 58
Genes specifically expressed during early stages of haemopoietic differentiation detected by DDRT-PCR. 58
Liposomes containing zoledronic acid: A new opportunity against cancer 58
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 58
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 58
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 58
Anti-myeloma activity of miR-125 mimics 58
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 57
[Extended subcutaneous mastectomy. A new type of operation in non-destructive surgery of breast neoplasms]. FT La mastectomia sottocutanea allargata. Un nuovo tipo d'intervento nella chirurgia non demolitiva della neoplasia mammaria. 57
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 57
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 57
Mir-221/222 are promising targets for innovative anticancer therapy 56
Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. 56
PEGylated Aqueous core PLA-nanocapsules as efficacious gene delivery vehicle 56
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 56
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 56
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 56
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 56
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 56
miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma 56
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 55
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 55
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 55
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 55
[Magnesium salts in the treatment of ventricular tachycardia]. FT I sali di magnesio nel trattamento della tachicardia ventricolare. 55
Totale 7.252
Salva come PNG Salva come JPEG
Categoria #
all - tutte 188.992
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 188.992
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021162 0 0 0 0 0 0 0 0 0 82 65 15
2021/20221.151 27 6 17 333 87 20 29 249 114 97 149 23
2022/20232.838 787 108 110 204 299 234 23 198 425 171 228 51
2023/20241.557 347 158 127 110 104 379 45 61 13 51 65 97
2024/20254.484 615 274 203 134 251 564 126 163 510 266 448 930
2025/20268.749 454 966 1.028 1.709 916 362 1.222 549 1.072 471 0 0
Totale 19.645